CD274 and neoplasm: Trastuzumab can also upregulate PD-1 and PD-L1 expression, induce expansion of tumour specific CD4 and CD8 T-cells and modulate MHC class II expression [63,64,65], which could enhance the efficacy of immune checkpoint inhibitors.